DE69813070D1 - Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex - Google Patents

Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex

Info

Publication number
DE69813070D1
DE69813070D1 DE69813070T DE69813070T DE69813070D1 DE 69813070 D1 DE69813070 D1 DE 69813070D1 DE 69813070 T DE69813070 T DE 69813070T DE 69813070 T DE69813070 T DE 69813070T DE 69813070 D1 DE69813070 D1 DE 69813070D1
Authority
DE
Germany
Prior art keywords
diseases
oral administration
drug preparation
preparation
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69813070T
Other languages
English (en)
Other versions
DE69813070T2 (de
Inventor
Haruo Yoshii
Yuriko Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Publication of DE69813070D1 publication Critical patent/DE69813070D1/de
Application granted granted Critical
Publication of DE69813070T2 publication Critical patent/DE69813070T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69813070T 1997-01-30 1998-01-30 Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex Expired - Fee Related DE69813070T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9031311A JPH10212246A (ja) 1997-01-30 1997-01-30 経口投与用製剤

Publications (2)

Publication Number Publication Date
DE69813070D1 true DE69813070D1 (de) 2003-05-15
DE69813070T2 DE69813070T2 (de) 2003-12-04

Family

ID=12327752

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813070T Expired - Fee Related DE69813070T2 (de) 1997-01-30 1998-01-30 Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex

Country Status (10)

Country Link
US (1) US6187803B1 (de)
EP (1) EP0864323B1 (de)
JP (1) JPH10212246A (de)
KR (1) KR100533399B1 (de)
CN (1) CN1167466C (de)
AT (1) ATE236615T1 (de)
AU (1) AU735950B2 (de)
CA (1) CA2228017A1 (de)
DE (1) DE69813070T2 (de)
TW (1) TW544316B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566386B2 (en) 1993-08-09 2003-05-20 Nippon Zoki Pharmaceutical Co., Ltd. Immunomodulating and antiinflammatory agent
JP2000143537A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 細胞接着分子発現抑制剤
JP2000143536A (ja) 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 抗浮腫剤
WO2003028668A2 (en) * 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
PT2301965E (pt) 2002-10-16 2015-05-20 Purdue Pharma Lp Anticorpos que se ligam a ca 125/0722p associado a células e métodos para a sua utilização
US20090226367A1 (en) * 2005-03-11 2009-09-10 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
KR100723251B1 (ko) * 2005-03-18 2007-05-29 전숙영 알레르기 질환의 치료를 위한 약학적 조성물, 그의 용도 및알레르기 질환의 치료방법
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
KR100756974B1 (ko) * 2006-03-16 2007-09-07 전숙영 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
US8163308B2 (en) 2007-05-10 2012-04-24 Rajesh Shah Homeopathy-based formulation
EP3210618A1 (de) * 2010-04-23 2017-08-30 Probiotec Limited Zusammensetzung beinhaltend lactoferrin und immunoglobulin zur behandlung von ekzemen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873697A (en) 1972-11-11 1975-03-25 Mack Chem Pharm Histamine antigen
US4705685A (en) * 1982-05-17 1987-11-10 Mcmichael John Methods and materials for treatment of disease states involving immunological factors
US4704273A (en) 1982-05-17 1987-11-03 Mcmichael John Methods and materials for treatment of rheumatoid arthritis
US4705687A (en) 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US5112738A (en) 1985-07-03 1992-05-12 Miles Inc. Histamine derivatives, immunogen conjugates and antibodies raised thereto
US4812449A (en) 1986-07-03 1989-03-14 Scripps Clinic And Research Foundation In situ active compound assembly
US5244902A (en) 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
IT1237475B (it) 1989-10-06 1993-06-07 Allergeni modificati chimicamente e procedimento per la loro preparazione
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JP3193205B2 (ja) 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
JPH0959180A (ja) 1995-08-11 1997-03-04 Nippon Zoki Pharmaceut Co Ltd 活性化免疫グロブリン

Also Published As

Publication number Publication date
US6187803B1 (en) 2001-02-13
AU5279098A (en) 1998-08-06
KR100533399B1 (ko) 2007-03-15
CA2228017A1 (en) 1998-07-30
ATE236615T1 (de) 2003-04-15
CN1192929A (zh) 1998-09-16
CN1167466C (zh) 2004-09-22
EP0864323A1 (de) 1998-09-16
AU735950B2 (en) 2001-07-19
KR19980070794A (ko) 1998-10-26
EP0864323B1 (de) 2003-04-09
JPH10212246A (ja) 1998-08-11
TW544316B (en) 2003-08-01
DE69813070T2 (de) 2003-12-04

Similar Documents

Publication Publication Date Title
CY2013041I1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
DE69813070D1 (de) Pharmazeutische Zubereitung zur oralen Anwendung enthaltend einen Histamin-Immunoglobulin Komplex
ATE311903T1 (de) Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
DE69738948D1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
TW200607807A (en) Macrocyclic beta-secretase inhibitors
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HUP0204023A2 (hu) Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények
TW200621249A (en) Substituted amide beta secretase inhibitors
ATE141599T1 (de) Kondensierte polyzyklische verbindungen, zusammenstellungen, verfahren zur herstellung und deren anwendung als paf-antagonistische, antihistaminische und/oder anti-inflammatorische agenzien
DK0639079T3 (da) Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme
ATE192655T1 (de) Verwendung von histamin-gamma-globulin zur herstellung eines immunomodulierenden und antiinflammatorischen agens
DE60237363D1 (de) Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
JP2006511555A5 (de)
HUP0202862A2 (hu) A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény
WO1992012715A3 (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
EA200400549A1 (ru) Лечение сепсиса введением малых доз ингибитора пути тканевого фактора (tfpi)
ATE469907T1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
WO2005041864A3 (en) Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
HUP0400115A2 (hu) Gyógyászati készítmény fulvesztrant intramuszkuláris beadására
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
PH12021551152A1 (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee